Current use of immunosuppressive agents in inflammatory bowel disease patients in East China

Huang, Lijuan; Zhu, Qin; Lei, M.; Cao, Qian

doi:10.3748/wjg.15.3055

Cited by 15 publications

(23 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies from Asia have shown that myelotoxicity occurred in approximately 20–40% of patients receiving AZA for treatment of IBD, which is much higher than that reported in studies from western countries (around 7%) . In our study, including 252 patients with 349 events, only 14 (14/349, 4.0%) had adverse events during AZA maintenance treatment, which was in consistent with two previous Japanese studies .…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Low 6‐thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease

Feng

Guo

Zhang

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

“…The recommended dose of AZA is 2.0 to 2.5 mg/kg/day in western population . However, lower dose of AZA was recommended, and higher rates of adverse events such as myelotoxicity were observed in Asian patients with CD …”

Section: Introductionmentioning

confidence: 99%

Low 6‐thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease

Feng

Guo

Zhang

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…However, a single centre review from East Asia found that of 227 patients 61 had indications for immunosuppressive agent use but were prescribed in only 34%. Of the 34%, 38% received a sub‐therapeutic dose with no attempt to increase the dose 192 . These differences in prescribing may relate to cost or limited experience in managing these medications 17 …”

Section: Medical Therapymentioning

confidence: 99%

Inflammatory bowel disease in Asia: A systematic review

Prideaux

Kamm

Cruz

et al. 2012

J of Gastro and Hepatol

289

249

View full text Add to dashboard Cite

The incidence and prevalence of inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are lower in Asia than in the West. However, across Asia the incidence and prevalence of IBD has increased rapidly over the last two to four decades. These changes may relate to increased contact with the West, westernization of diet, increasing antibiotics use, improved hygiene, vaccinations, or changes in the gut microbiota. Genetic factors also differ between Asians and the Caucasians. In Asia, UC is more prevalent than CD, although CD incidence is rapidly increasing in certain areas. There is a male predominance of CD in Asia, but a trend towards equal sex distribution for UC. IBD is diagnosed at a slightly older age than in the West, and there is rarely a second incidence peak as in the West. A positive family history is much less common than in the West, as are extra-intestinal disease manifestations. There are clear ethnic differences in incidence within countries in Asia, and an increased incidence in IBD in migrants from Asia to the West. Research in Asia, an area of rapidly changing IBD epidemiology, may lead to the discovery of critical etiologic factors that lead to the development of IBD.

show abstract

“…Conventional treatment of colitis with an unspecific immune suppressor such as azathioprine may reduce duration of disease and help remission; however, there are severe side effects [12]. Many colitis drugs turn to unconventional treatments in the hopes of reducing the symptoms of disease, and about 40% of IBD patients use some form of mega-vitamin therapy, including herbal/dietary supplements.…”

Section: Introductionmentioning

confidence: 99%

Fermented Herbal Formulas KIOM-MA128 Ameliorate IL-6-Induced Intestinal Barrier Dysfunction in Colon Cancer Cell Line

Park

Kim

Lee

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) comprises Crohn's disease (CD) and ulcerative colitis (UC). IBD increases the risk of colorectal cancer (CRC), depending on the extent and duration of intestinal inflammation. Increased IL-6 expression has been reported in IBD patients, which may be associated with intestinal barrier function through discontinuous tight junction (TJ). KIOM-MA is a specific agent for allergic diseases and cancer, and it is composed of several plants; these herbs have been used in traditional oriental medicine. We fermented KIOM-MA, the product of KIOM-MA128, using probiotics to improve the therapeutic efficacy via the absorption and bioavailability of the active ingredients. In this study, we demonstrated that KIOM-MA/MA128 exhibited anticolitis effects via the modulation of TJ protein. Interleukin-6 resulted in a dose-dependent decrease in the TER and an increase in the FITC-dextran permeability; however, pretreatment with 400 µg/ml KIOM-MA/MA128 resulted in a significant increase in the TER and a decrease in the FITC-dextran permeability via IL-6 induction. Furthermore, protein and mRNA TJ levels remained stable after pretreatment with 400 µg/ml KIOM-MA/MA128. Moreover, KIOM-MA/MA128 suppressed the expression of PLCγ1 and PKC. Taken together, these findings suggest novel information and clue of the anticolitis effects of KIOM-MA128 via regulation of tight junction.

show abstract

Current use of immunosuppressive agents in inflammatory bowel disease patients in East China

Abstract: AIM:To investigate immunosuppressive agents used to treat inflammatory bowel disease (IBD) in East China.

Cited by 15 publications

References 28 publications

Low 6‐thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease

Low 6‐thioguanine nucleotide level: Effective in maintaining remission in Chinese patients with Crohn's disease

Inflammatory bowel disease in Asia: A systematic review

Fermented Herbal Formulas KIOM-MA128 Ameliorate IL-6-Induced Intestinal Barrier Dysfunction in Colon Cancer Cell Line

Contact Info

Product

Resources

About